Moderna Inc. (MRNA) said Thursday that it is developing a single dose vaccine that combines a booster against COVID-19 and a booster against flu.
The company announced significant advances across its portfolio of mRNA pipeline programs being presented at the Company's fifth annual R&D Day Thursday.
The company said it is making progress on enrolling patients in its rare disease programs, and it is fully enrolled in its personalized cancer vaccine trial.
Moderna continues to scale, now with 37 programs in development across 34 development candidates1, including 22 in ongoing clinical studies.
For comments and feedback: editorial@rttnews.com